#Glucagon

3 stories

Clinical Trials June 6, 2026 · View digest

Retatrutide Arrhythmia and MACE Safety Signal at ADA 2026: 7 of 403 Arrhythmias and 3 MACE on Drug Versus None on Placebo

STAT reported June 6 that new safety data presented at ADA showed seven of 403 retatrutide-treated patients experienced arrhythmias and three had major cardiovascular events, compared with none in the placebo group. The signal had been a watch item ahead of ADA because retatrutide adds glucagon-receptor activity to GLP-1 and GIP, raising heart-rate and energy-expenditure mechanisms that have not appeared in the same way for semaglutide or tirzepatide. Lilly's larger TRIUMPH-OUTCOMES cardiovascular trial reads out in 2027.

Research April 18, 2026 · View digest

STAT News: GLP-1 Pioneers DiMarchi and Tschöp Propose Dropping GLP-1 as a Drug Target for Obesity

Richard DiMarchi and Matthias Tschöp — whose work enabled Eli Lilly's Zepbound and the modern GLP-1 class — published a peer-reviewed draft paper arguing that targeting GIP and glucagon receptors alone, without GLP-1, may deliver comparable weight loss without the nausea and vomiting that plague current therapies. The experimental molecule, backed by BlueWater Biosciences, challenges the central dogma of obesity drug design. Results are preclinical and must still translate to humans.

Clinical Trials April 10, 2026 · View digest

MetaVia Doses First Patient in Higher-Dose DA-1726 GLP-1/Glucagon Dual Agonist Phase 1 Study

MetaVia dosed the first patient in a higher-dose Phase 1 study of DA-1726, its GLP-1 and glucagon dual agonist for obesity treatment, marking continued advancement in next-gen weight loss drugs.